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Highlights:  
 OMPs are often cost-ineffective and their value is characterised by greater 
uncertainty;  
 New EU/national HTA programmes for (ultra-)OMPs aim to overcome these 
challenges;  
 These programmes are stand-alone or supplementary to standard HTA/payer 
processes;  
 Wider considerations from patients and clinicians contribute to understanding value 
of OMPs;  
 Cross-border collaboration is essential to deliver OMPs that demonstrate value for 
money. 
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Abstract  
Background 
Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were 
identified in Advance-HTA. Since then, new initiatives have been developed to specifically 
address issues related to HTA of OMPs.  
 
Objective and Methods 
This study aimed to understand why these new HTA initiatives in England, Scotland and at 
European-level were established and whether they resolve the challenges of OMPs. The work 
of Advance-HTA was updated with a literature review and a conceptual framework of 
clinical, regulatory and economic challenges for OMPs was developed. The new HTA 
programmes were critiqued against the conceptual framework and outstanding challenges 
identified. 
 
Results 
The new programmes in England and Scotland recognise the challenges identified in 
demonstrating the value of ultra-OMPs (and OMPs) and that they require a different process 
to standard HTA approaches. Wider considerations of disease and treatment experiences 
from a multi-stakeholder standpoint are needed, combined with other measures to deal with 
uncertainty (e.g. managed entry agreements). While approaches to assessing this new view of 
value of OMPs, extending beyond cost/QALY frameworks, differ, their criteria are similar. 
These are complemented by a European initiative that fosters multi-stakeholder dialogue and 
consensus about value determinants throughout the life-cycle of an OMP. 
 
Conclusion 
New HTA programmes specific to OMPs have been developed but questions remain about 
whether they sufficiently capture value and manage uncertainty in clinical practice.  
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Introduction  
At local and national levels, Health Technology Assessment (HTA) is increasingly being 
used to inform drug coverage decisions to ensure that rational, evidence-based choices are 
made within a limited budget [1].  OMPs generally undergo the same HTA processes as 
drugs for more prevalent diseases [2, 3], even if an orphan designation distinction is 
previously made at regulatory level. Is this approach fair, or should different approaches be 
used? 
 
Rare diseases affect small patient numbers (with a prevalence of less than five in 10,000 in 
Europe), and are life-threatening, debilitating and frequently genetically acquired [4].  An 
estimated number of 5,000 to 8,000 rare diseases exist, affecting 6-8% of the population in 
Europe. Based on the principle of equity [5], where "patients suffering from rare conditions 
should be entitled to the same quality of treatment as other patients” [6], incentives were 
implemented in medicines regulation processes in the EU and other countries to stimulate 
research and development for rare disease treatments [7].  Medicinal products treating a rare 
disease are eligible to receive an orphan designation by regulators. Upon receiving this 
designation, they are referred to as Orphan Medicinal Products (OMPs), and benefit from 
incentives that allow expedited authorisation with more limited evidence than other medicinal 
products. However, this does not give patients automatic access to the treatments, as their 
reimbursement often depends on HTA.  
 
A Work Package in the Advance-HTA project systematically investigated HTA decision 
processes for a sample of ten OMPs between October 2007 and December 2012 in four 
European countries (England, Scotland, Sweden and France). It identified a number of issues 
that HTA bodies faced when making these difficult coverage decisions [8]. Although these 
issues are also encountered for drugs treating more prevalent diseases, they are more 
challenging for OMPs [9]. When economic evaluation is used in HTA, OMPs often fail to 
meet standard cost-effectiveness criteria due to their high acquisition costs and the uncertain 
evidence-based produced, and so would generally not be recommended for coverage [5, 10-
12].  Despite the common problems with OMPs, there were different approaches to dealing 
with them in the four countries, with different issues raised as most important and different 
judgments about the acceptable levels of uncertainty. This included, for example, accepting 
greater uncertainty when considering the orphan status or conditional licensing of the 
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medicine, imposing future reassessments, or improving the incremental cost-effectiveness 
ratio (ICER) with a patient access scheme [8]. This raised the question as to whether we 
[society] are willing to pay more for rare disease patients [13]. A number of surveys aiming 
to elucidate this question found little support when resources are taken from more prevalent 
diseases, but a positive response if it is for more serious conditions with no treatment 
alternatives [10, 11, 14-17]. This emphasizes the recognized need for more suitable 
approaches to appraising orphan drugs, particularly with regards to the challenges 
encountered during the assessments. 
 
Since the Advance-HTA project, new HTA programmes specific for OMPs or ultra-OMPs 
(treating less than one in 50,000) have recently been developed and/or implemented within 
Europe (e.g. the Patient and Clinician Engagement (PACE) meeting and ultra-OMP decision-
making programmes at the Scottish Medicines Consortium (SMC); the Highly Specialised 
Technology (HST) programme at the National Institute for Health and Care Excellence 
(NICE) in England; or the Mechanism of Coordinated Access (MoCA) to OMPs, a European 
initiative initiated during the Belgian EU Presidency [18]).  This research updated the 
literature search undertaken for the Advance-HTA project to identify challenges in assessing 
OMPs. It then developed a conceptual framework to explain these issues. The rationale for 
new HTA programmes for OMPs was then reviewed and compared with the HTA-level 
issues identified in the framework. The outputs of the new programmes were explored to 
examine their impact.  
 
Materials and methods  
Previous findings from the Advance-HTA project were used to summarise the types of 
challenges faced when dealing with OMPs in four countries [8, 19]. This was based on a 
document analysis of HTA reports issued by four HTA bodies in four countries (NICE in 
England, SMC in Scotland, the Dental and Pharmaceutical Benefits Board (TLV) in Sweden, 
and the Haute Autorité de Santé (HAS) in France).  This summary was generated by the lead 
author, and received two rounds of comments by non-institutional co-authors (KF, LA), to 
ensure their clarity and completeness.  A review of the literature was conducted to understand 
how issues relating to the assessment of treatments for rare diseases are reflected at HTA-
level.  The databases Web of Science and Medline were searched using the following MeSH 
heading: (“orphan drug” OR “rare disease” OR “rare condition” OR “rare disorder”) AND 
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(“uncertainty” OR “health technology assessment”). The abstracts were reviewed and 
selected if they referred to issues encountered with OMPs at HTA-level or to the type of 
uncertainty encountered with OMPs.  We also cross-checked the references included in the 
papers identified of interest, and searched the grey literature, including websites from key 
institutions or initiatives in the rare disease field (e.g. Eurordis, European Commission). On 
this basis, a conceptual framework was built summarising the challenges that arise due to the 
nature of OMPs in terms of drug development and their implications for HTA (Figure 1). 
 
Representatives leading new HTA programmes for OMPs and/or ultra-OMPs were invited to 
participate in this research. These included the HST programme at NICE, the PACE 
programme and ultra-OMP decision-making programme at SMC, and the MoCA project. 
SMC is the HTA body in Scotland that undertakes HTA for all medicinal products. Within 
this remit, new processes have been created for certain types of medicines (e.g. OMPs and 
ultra-OMPs), these have been referred to as “programmes” in this paper.  A questionnaire 
developed by some of the authors (EN, KF, LA) was sent by email to these representatives.  
It included open-ended questions about: (a) their definition of an OMP and ultra-OMP; (b) 
the reasons for establishing these new programmes; (c) a brief description of their processes 
and how it differed from standard HTA approaches; (d) whether the issues pertaining to 
OMPs previously identified are commonly encountered in their setting; and (e) whether they 
can summarise the impact of their new programmes.  Responses were compiled and 
organized to highlight the key characteristics for each question and contrasts across countries. 
Follow-up questions were sent when necessary. All co-authors reviewed and commented on 
versions of the manuscript.  The responses and feedback were received from representatives 
participating in these new programmes, and reflect their views and not those of the 
organisations they represent. 
 
Results  
Issues with OMPs  
OMPs often exceed cost-effectiveness thresholds in HTA due to lack of evidence about 
clinical benefit and high acquisition costs. Moreover, evidence on their cost-effectiveness is 
typically characterized by greater uncertainty.  This can lead to rejection through the routine 
approval process, or funding restricted to subgroups of patients where their use is considered 
most effective or cost-effective [5, 11, 20-23]. 
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These challenges emerge from the clinical, regulatory and economic obstacles encountered 
throughout the OMP development process (Figure 1).  Clinical challenges relate to the scarce 
scientific literature and number of clinical experts available [24], where often little is known 
about the diseases‟ epidemiology, natural history or best treatment pathways [25], [26].  This 
affects the ability to run confirmatory trials in terms of design, e.g. lack of agreement on 
relevant endpoints [22], treatment pathways or appropriate trial durations [22], lack of active 
comparator [27], lack of validated patient reported outcome instruments [28] and conduct 
(e.g. recruitment [25], diagnosis [24], multiple clinical trial sites due to the few patient 
numbers [24]). The small patient numbers and relatively short duration of these clinical trials 
often imply that intermediate outcomes such as biomarkers or the six-minute walk test are 
studied rather than longer-term clinical outcomes [22]. These, in addition to the regulatory 
incentives for expedited approval based on phase II trials, may result in lower quality 
evidence generation for OMPs [29, 30]. The statistical power to detect clinically meaningful 
outcomes from these often small-scale trials is limited [31].  Given the severity, chronicity, 
life-threatening and disabling nature of these rarer diseases, the economic, psychological, and 
quality of life burden is also frequently high for patients, their families and carers, the 
healthcare system and society [25, 27, 32]. 
 
<Figure 1. Conceptual framework of OMP development and assessment challenges> 
 
These challenges were reflected in the types of issues highlighted by the HTA bodies across 
the OMPs previously analysed in the Advance-HTA project (Figure 1, eAppendix A) [8].  
Misalignments with marketing authorisation incentives were seen, where some of the 
assessments relied on phase II trials following early marketing authorisation under 
exceptional circumstances or with conditional approval [8].  Other issues relating to the 
nature of these rare diseases included those around sample size and statistical power, clinical 
pathways, comparators, clinical, health-related quality of life or patient reported outcomes 
endpoints, trial duration, or subgroup data. The base case ICER estimates of NICE and 
SMC‟s assessment were generally high (> £30K/QALY in 60-70% of cases) and sensitivity 
analyses showed high levels of uncertainty.  This was a consequence of high acquisition 
costs, marginal benefits and uncertain evidence (Figure 1, sAppendix A) [8]. These are in line 
with the issues seen for OMPs highlighted by Menon and colleagues [9]. 
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New programmes for OMPs and ultra-OMPs  
Rationales 
It was generally recognized that OMPs do not usually prove to be cost-effective based on 
conventional HTA methods designed for common diseases. Over several years HTA bodies 
have been criticized about their evaluation processes for OMPs and ultra-OMPs [33, 34], 
where there may have been more leniency when dealing with them.  As a result, HTA bodies 
have been facing political pressures to change their processes and be more transparent. At the 
same time, research has been conducted to identify the types of issues HTA bodies faced for 
OMPs within these conventional processes. The aim of this paper was to compare how the 
new programmes being implemented are tackling the findings from this research. 
 
In England, NICE has been responsible for assessing selected ultra-OMPs since 2013 and 
established the new HST programme to do this [35].  HST‟s remit is to evaluate the benefits 
and costs of a technology within its marketing authorization for the treatment of a specific 
disease for national commissioning by NHS England using a specific decision-making 
framework.  About three ultra-OMPs undergo the HST process each year. The products are 
chosen in the same manner as other technologies through a topic prioritization process led by 
the Department of Health. Ultra-OMPs not selected for the HST programme undergo the 
usual commissioning process via NHS England. OMPs can undergo the same process as non-
OMPs at NICE (e.g. single or multiple technology appraisal process) or be part of the 
commissioning process at NHS England. The Department of Health mandates NICE to issue 
a coverage decision, which should be enacted within 90 days.  
 
In Scotland, SMC assesses all new medicinal products and new indications for existing 
products. Manufacturers make evidence submissions and SMC recommends routine, 
restricted, or not recommended use in NHS Scotland. If a manufacturer does not make a 
submission for a product, then it is not recommended for routine use. In 2013, three petitions 
were brought to the attention of the Scottish Parliament Health and Sport Committee about 
lack of access to ultra-OMPs due to not recommended advice from SMC. The Committee 
report to the Scottish Government prompted a major review of processes with all 
stakeholders, and led SMC to develop new, more flexible programmes for OMPs and ultra-
OMPs (and end-of-life treatments) in order to increase patient access.  These new approaches 
include the PACE meeting and the new decision-making framework for ultra-OMPs [36]. 
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At European-level, the challenges and discrepancies in access to OMPs across Member States 
triggered the implementation of the MoCA project [37].  The MoCA provides a mechanism 
for European countries to collaborate on access for patients with rare diseases to OMPs via a 
voluntary, dialogue-based approach, with flexible interactions between key stakeholders to 
agree on the value of OMPs [38]. This approach aims to facilitate a quicker and broader 
access to OMPs, to allow for greater equity in access to OMPs across Member States, and to 
better coordinate the collection of patient-reported outcomes and real-life experiences. Payers 
should benefit from a better documentation of the treatment‟s added value, more precise 
budget estimates and efficient price negotiations, while manufacturers gain a better 
predictability, rapid uptake of their products, and understanding of payers‟ expectations. 
Participation is initiated upon the manufacturer‟s expression of interest. MoCA is currently 
being piloted, and focuses on the early dialogue phase about evidence generation and how to 
provide access to these OMPs. 
 
New processes  
The HST evaluation process is similar to NICE‟s conventional technology appraisal 
processes, with the main difference being the criteria accounted for defined by HST‟s value 
framework [39]. When evaluating costs, the committee also considers the cost to the NHS 
and personal social services. It takes into account the total budget for specialised services and 
its allocation, as well as the scale of investment in comparable areas of medicine. The 
committee assesses what could be considered a reasonable cost for the medicine in the 
context of recouping manufacturing, research and development costs from sales to a limited 
number of patients. Interim methods for the HST programme are currently under review.  
  
In SMC‟s process, the New Drugs Committee drafts the HTA advice according to the 
standard clinical and cost-effectiveness framework. The manufacturer may request that SMC 
convenes a PACE meeting if the draft advice issued is to not recommend the use of the 
medicine [40]. Patients, clinicians and the pharmaceutical company then submit a written 
report to the PACE meeting, with patient and clinician representatives contributing to further 
discussions in person, leading to a joint PACE statement that is circulated in full to the SMC 
members, summarized in the Detailed Advice Document and highlighted in a verbal report 
by the PACE Chair during the SMC meeting. Additionally for OMPs, SMC will account for 
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additional criteria defined in their framework of explicit decision-making criteria for ultra-
OMPs [36]. This adds about one to three months to the standard 18-week SMC process. At 
this point in the process, the company also has the option to offer a new or revised Patient 
Access Scheme (confidential discount) to improve value for money.  
 
By contrast, the MoCA is not a standard HTA programme but a collaborative process that 
involves a sustained dialogue between the OMP developer, a group of payers and other 
stakeholders from various European countries [37]. Participants consist of companies with 
new products, EURORDIS, an umbrella patient organization, which also ensures the 
participation of relevant patient groups, and volunteers from the Medicine Evaluation 
Committee (MEDEV). The main difference with the parallel scientific advice at the European 
Medicines Agency (EMA) is that participation from the stakeholders is voluntary and not 
initiated by the applicant, allowing for participation in the dialogue of smaller countries. It 
also differs from the early dialogue with HTA bodies in that it focuses on practical, 
pragmatic, legal and economic aspects of reimbursement decision-making, and integrates the 
HTA-relevant questions into this context.  
 
Appraisal criteria  
HST‟s decision-making criteria include considerations around the nature of the condition, 
impact of the new technology, including its impact beyond direct health benefits and on the 
delivery of specialized services, costs to the NHS and Personal Social Services, and value for 
money [39]. For each criterion, a sub list of criteria is provided (Table 1). The methods 
guidelines give freedom in the form of the health economic evaluation that can be used, e.g. 
cost-consequence, cost-utility. To date, all companies have chosen to submit a cost-utility 
analysis. 
 
The SMC first considers the traditional HTA measures, e.g. ICER, while PACE assesses 
where these did not capture certain aspects of the disease or conditions by giving patients 
and clinicians the opportunity to comment on their experiences. This includes clinical, 
psychological and social issues, such as the added value of the medicine for the patients, 
their families and carers.  Participants are asked to focus on quality of life issues, which 
could be improved by taking the medicine such as the ability to continue work or 
education, treatment convenience, ability to improve symptom management (e.g. pain, 
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extreme tiredness), relieve psychological distress, enable self-care or maintain 
independence and dignity.  In addition to a PACE meeting, the assessment of an ultra-OMP 
is based on a dedicated framework of explicit decision-making criteria, which include the 
same criteria as for the HST programme, setting out the higher level criteria only (Table 1) 
[36]. A cost-utility analysis is requested as part of the company submission to assess value 
for money. Other forms of economic evaluations, including cost-consequence analysis, are 
accepted if the submitting company believes an evaluation using QALYs is not feasible.   
 
By contrast, the MoCA aims to facilitate a dialogue amongst key stakeholders throughout 
the OMP‟s development life cycle. Dialogue may start at any point during the lifecycle of 
an OMP and results in a final report containing learnings and recommendations, which is 
confidential and non-binding, unless otherwise agreed. Companies as well as payers are 
free to opt out at any time (until a contract is signed) and the process is currently free of 
charge. 
 
<Table 1. Assessment criteria accounted for within the HST and PACE programmes > 
 
Dealing with uncertainty commonly encountered with OMPs  
All programmes agreed that the challenges highlighted in Figure 1 (eAppendix A) are in line 
with those commonly encountered for both OMP and ultra-OMPs.  The common 
characteristic of NICE and SMC‟s programmes is to account for a broader range of criteria 
and include patient and clinician input to help address uncertainty and better understand the 
value of a product.  The decision then relies on the Committee‟s judgment as to whether this 
evidence is sufficient to overcome greater uncertainty. This may be combined with other 
measures helping deal with uncertainty such as the ability to implement a Managed Access 
Agreement (MAA) (which is a type of outcomes based managed entry agreement) at HST, or 
Patient Access Schemes (PAS) (e.g. simple discounts) at HST and SMC (Table 2).   
 
A MAA scheme facilitates access to ultra-OMPs, whilst generating valuable evidence in 
collecting „real-world‟ data. All stakeholders agree on a set of criteria and conditions that 
need to be fulfilled by patients, clinicians and industry. These include conditions and criteria 
for patient eligibility, start and stop criteria, data collection and monitoring (e.g. 
implementation of registries, data collected and assessments to be made), appeal process, 
ownership of data, or exit strategy [41]. There may be some additional financial arrangements 
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between payers and the relevant pharmaceutical company. At the end of the MAA period, the 
product is re-evaluated via the HST process. If no benefit is gained, the ultra-OMP will no 
longer be available to any patient via the NHS. These drugs are usually dispensed within 
specialized services, which allows for patients to receive expert care and infrastructure to 
manage patients with the condition in question.  
 
<Table 2. Products assessed by SMC ultra-OMP programme and informed by PACE (May 
2014 – March 2016)> 
 
MoCA aims to address these issues in advance through the conversations among stakeholders 
about how to best generate evidence for HTA and payers with reasonable resources, defining 
patient-relevant outcomes, demonstrating cost-effectiveness, and designing pathways for 
equitable and sustainable financing.  This involves discussions about the design and 
implementation of registries, the feasibility of managed entry agreements, and delivery 
pathways (e.g. how to establish or designate treatment centers for very rare diseases with 
cross-border access, where it is not feasible to establish one or more centers per Member 
State – a particularly relevant issue for advanced therapy medicinal products). 
 
Challenges encountered with these new programmes 
The HST programme is challenged by the number of new products needing an evaluation and 
its capacity to undertake only three evaluations per year. Other challenges include the ability 
to assess and manage the uncertainty in the evidence submitted. With limited natural history 
data, short and small-scale trials, careful consideration of the evidence in line with the 
company value proposition is needed. New approaches are also needed to allow better 
management of the risk burden relating to the uncertain evidence that the NHS is willing to 
bear. 
 
The SMC ultra-OMP framework allows companies to make a submission that emphasizes the 
wider benefits of medicines that may not be easily captured in the QALY. Although the 
Committee now has more flexibility to accept medicines with a higher ICER than would 
conventionally have been accepted, the extremely high acquisition costs of many of these 
medicines, coupled with very significant uncertainty about the magnitude and duration of 
clinical benefits, means that the most plausible ICER may be £500,000 or more, which is 
well above the perceived willingness-to-pay threshold (Table 2). 
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The MoCA project‟s main challenge is that there is no single payer voice. Each country has 
different health care systems, laws, economies, and priorities. It is not always possible to find 
“one-size-fits-all” solutions - ultimately, each national authority will have to make a decision, 
but this may be expedited through the previous discussions. There are also challenges in 
designing appropriate registries, which can accommodate the needs of regulators, HTA 
bodies and payers, and are workable across borders. Moreover, at many payer institutions 
resources for this type of activity are scarce. 
 
Impact of new programmes 
To date, three ultra-OMPs have undergone the HST process and were approved, three are in 
the process.  Two of the three were approved under an MAA. For example, elosulfase alfa in 
the treatment of mucopolysaccharidosis type IVa in adults and children was approved under 
the condition of a MAA achieved through a working partnership between NHS England, 
NICE, a patient organization, the manufacturer and a clinical expert.  The MAA was 
designed to assess patient response to treatment based on pre-defined criteria monitoring 
clinical data and quality of life. The outcomes covered include a combination of registry data 
and condition-specific outcome measures. The MAA also included confidential negotiated 
commercial terms and a stopping clause for those patients not meeting treatment targets [41].  
 
Since the introduction of the PACE programme (May 2014-September 2016), the acceptance 
rate for eligible medicines has increased by 58% compared to the 2011-2013 period, from 
48% to 76%, and the number of non-submissions has reduced by around a third. The PACE 
programme has proven helpful to facilitate joint dialogue between patient groups, clinicians 
and HTA staff to highlight the impact of a condition on patients and their personal experience 
together with the expected wider benefits and disadvantages of a new medicine. The PACE 
statement is expected to be a significant factor in the SMC decision.  For example, the output 
of the PACE meeting assessing ruxolitinib in the treatment of disease-related splenomegaly 
in adults clearly illustrated the symptom burden in primary myelofibrosis and its devastating 
effect on the quality of life for patients and their families.  The benefits from treatment 
response were also highlighted in terms of the ability to return to a virtually normal life and 
in some cases to work, the improvement of family relationships following a reduced 
dependency on carers, the easing of the psychological burden on patients, and their ability to 
regain their personal dignity and independence. Patients were also less likely to need 
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inpatient or outpatient care. The utility values for treatment were derived using a relatively 
new condition-specific HRQol measure, the MF-8D. The novelty of this measure, together 
with the relatively high utility values from responding patients, was one of several key 
uncertainties in the economic case. The knowledge of the patient experience derived from the 
PACE process provided some reassurance to decision-makers in this context. At this stage, a 
Patient Access Scheme improving the cost-effectiveness of the medicine was also submitted 
by the company.  For elosulfase alfa, previously discussed within the HST context, a number 
of considerations about the condition‟s severity and treatment benefit were also accounted for 
during the PACE meeting and within the ultra-OMP decision-framework. These were not 
sufficient, and a negative recommendation was issued because of weaknesses in the 
economic case and the high ICER (> £800,000/QALY), where the medicine was unlikely to 
provide value for money.  
 
To date, no product discussions within the MoCA framework have advanced to the point of 
specific agreements on managed entry. Companies participating in the discussions have 
termed them as very useful to gain insights into the problems payers face, and into the 
outcomes that matter to patients and payers. This is especially important for smaller and 
newer companies, which are those most likely to find the MoCA process useful [42]. Payers 
get an earlier opportunity to plan for introducing the new therapies and developing new 
models for access.  
 
 
Discussion  
While the challenges in dealing with orphan drugs are generally recognized, the approaches 
to tackle these varied.  Differences were seen in the technologies selected to undergo these 
new progammes. The same ultra-OMPs do not necessarily undergo NICE‟s HST and SMC‟s 
ultra-OMPs evaluation programmes despite their common definition. Those not selected by 
the Department of Health for NICE‟s HST programme proceed through the usual 
commissioning process, where NHS England makes their own decision on how to provide 
access. OMPs undergo conventional HTA processes at NICE and SMC. In the latter case, 
additional considerations are accounted for via the PACE programme for those drugs that 
were not recommended during the initial standard HTA assessment by the New Drugs 
Committee.  
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The main commonality across these new programmes at NICE and SMC is the recognition 
that the QALY may not capture all elements of value and that wider considerations are 
needed from a multi-stakeholder standpoint. These considerations are accounted for during 
the deliberative process and contribute to accepting greater uncertainty and high ICERs. This 
is one way forward to recognising other sources of evidence through greater patient, clinician 
and public participation (patient experiences, care pathways) [43], as well as the value of 
qualitative evidence [2, 43].  
 
When comparing the criteria across these programmes, the information requested is similar 
(Table 1). These criteria are accounted for through NICE‟s consultee submissions or SMC‟s 
PACE statements and ultra-OMP explicit decision-making framework, and discussed during 
the appraisal committees‟ deliberations.  While NICE has a committee dedicated to the HST 
programme, the same Committee evaluates all drugs at SMC. Additionally, NICE‟s patient 
and clinician submission templates provide more detailed guidance about the type of 
evidence to be provided compared to SMC‟s PACE submission template [35, 44]. It is not 
clear whether this influences the level of detail provided during these processes. Our 
examples also showed that these additional criteria may not be sufficient to accept poor value 
for money (e.g. SMC for elosulfase alfa).  One of the main issues highlighted by SMC, but 
not by NICE, are the extremely high ICERs encountered. This suggests that despite 
accounting for similar criteria (Table 1), differences may be seen in their consideration.  
 
While one of the main criticisms of traditional cost-effectiveness models is the failure to 
capture multiple attributes of the value of an OMP, a number of studies have tried to define 
these [societal preferences]. We have seen earlier that rarity does not justify a special status, 
but other attributes may. One recent study identified some of these societal preferences, 
which included disease severity, the rule of rescue (priority to the more urgent conditions), 
other patient attributes (e.g. age, parent and caregiver status), and (non) smokers [24]. 
Paulden and colleagues (2015) have performed a scoping review of the social value 
arguments put forward and against the reimbursement of orphan drugs [42]. They propose a 
value framework with the factors that should be considered in the decision, which include 
value-bearing factors (e.g. disease-, treatment-, population-, and socio-economic-related 
factors), opportunity cost-determining factors (e.g. cost of treatment, budget impact), and 
other factors (e.g. feasibility of diagnosis and of treatment). They also consider the patient, 
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physician and societal preferences, as well as the rule of rescue, the equity principle and the 
rights based approach. Most of these are captured in the ultra-OMP frameworks, either 
through their eligibility criteria (e.g. prevalence), their process (e.g. accounting for 
stakeholder input), or in the criteria considered. The following, however, were not captured: 
the identifiability of the treatment beneficiaries (tendency to give preference to visible 
individuals, e.g. rule of rescue), the treatment‟s innovative nature [45], the feasibility of 
diagnosing the disease and providing the treatment, industrial and commercial policy, legal 
considerations, or certain patient attributes. Similar criteria were also accounted in the ultra-
OMP frameworks to those defined as the normative universal criteria included in the 
EVIDEM framework, which aims “to evaluate interventions and facilitate their prioritization 
using a comprehensive set of decision criteria” based on the criteria rooted in different ethical 
positions” [46].  These examples suggest that the criteria included in the ultra-OMP 
frameworks correspond to those highlighted as relevant for both OMPs and non-OMPs, 
despite in some instances, a lack of consensus in the literature as to whether these should be 
considered. 
 
Whether the ICER is still relevant for ultra-OMPs is obviously a key question. For example, 
since 2002, a distinction has been made in Belgium between the reimbursement criteria for 
OMPs and other drugs. Cost-effectiveness is not mandatory for OMPs. An OMP is 
reimbursed if there is a high medical need, a clinically significant effect and an acceptable 
budget impact. Interestingly NICE and SMC do review budget impact, but it has not been a 
part of decision-making. This is an important consideration for ultra-OMPs. NICE utilises a 
national risk-sharing scheme to support implementation via the HST programme. There is 
currently no comparable scheme in NHS Scotland. The SMC remit excludes affordability. 
 
However, as we see increasingly high prices for orphans and ultra-OMPs, some mechanism is 
needed to ensure fairness for all those in the health system including the opportunity costs 
these high cost OMPs will bring. While both NICE and SMC's programmes recognise the 
need to go beyond cost/QALY estimates, one important consideration is how these new 
programmes are being implemented and whether they ensure accountability for 
reasonableness and consistency in the way the criteria are accounted for. Their explicit 
consideration during the deliberative process is already one step forward to making sure they 
are examined, but more could be done to gain international multi-stakeholder agreement on 
the wider elements of value and to ensure that deliberative processes document how these 
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new elements have contributed to the decision. New approaches such as multiple criteria 
decision analysis (MCDA) not only ensure consideration of these elements, but also give 
them an explicit weight that can be derived through stakeholder participation [47]. MoCA 
takes account of this. Additionally, other features encountered with orphan drugs include 
issues such as of salami-slicing, drug repurposing or the making of excessive profits [10]. 
The current systems fail to account for multiple indications and whether excessive profits are 
being made or to distinguish between products developed de novo and “repurposed” drugs, 
with much lower development costs. These would not be accounted for explicitly when 
assessing their value, but should be regarded by the decision-makers during the deliberative 
process.  
 
While such innovative approaches and greater stakeholder participation and inclusion of 
other forms of evidence may help go beyond the ICER, uncertainty will still be present. This 
could be managed by additional evidence generation after HTA approval to allow 
reassessment, e.g. via MAA/PAS, registries and real world data to collect natural history and 
longer term outcomes [2]. This was seen in our illustrative examples, and allowed to better 
deal with uncertainty or high costs, sharing the associated risks with the manufacturer, or 
accepting uncertainty until additional evidence is available.  
 
Both the HST and SMC programmes for OMP and ultra-OMPs are at early stages and 
currently under review [48]. This is also the case for MoCA. There are still a number of open 
questions about their application, and the ongoing issue of having to deal with extremely high 
ICERs and uncertain evidence. The question therefore arises as to whether these processes 
are still sufficient or whether there is a need to look at new ways to assessing value. The 
potential added value of the MoCA project is of key importance within this context, in 
fostering a multi-stakeholder dialogue in view of reaching greater consensus when discussing 
the determinants of a product‟s value at earlier stages and throughout the drug development 
process. This early and continuous dialogue will contribute to improving the efficiency (and 
effectiveness) of drug development [49]. The importance of this approach is highlighted by 
the Adaptive Pathways initiative of the EMA, which does not specifically address OMPs, but 
does include them [50]. In a context where a number of new value frameworks for 
prescription drugs and OMPs are being developed [51, 52], MoCA has the potential to bring 
together these new models and gain more experience in order to find out how best to 
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integrate these processes and reduce the complexities encountered from these multiple 
systems. 
 
 
Conclusions 
Two HTA bodies in the UK have recognized that OMPs or ultra-OMPs operate in a context 
of greater uncertainty due to clinical, regulatory and economic challenges and responded to 
this by creating new bespoke programmes for these products. These encourage alternative 
economic models to the standard cost-utility approaches and managed entry agreements in 
the form of patient access schemes and managed access agreements to collect real world data. 
In addition, the HTA appraisal decision-making criteria is extended beyond the cost/QALY, 
to consider a more holistic framework that considers disease and treatment experiences and 
uncertainty from a range of stakeholders. The question arises as to whether these new 
programmes and decision-making frameworks will be successful in capturing value and 
dealing with uncertainty. What is needed are trials that answer the question that payers and 
HTA bodies will pose. Payers have recognised this issue and MoCA is seeking to foster 
multi-national and multi-stakeholder dialogue and reach consensus about the determinants of 
a product‟s value throughout the drug development process. Although discussions around 
specific products are confidential, the process needs to be evaluated and the challenges and 
issues faced in all these programmes need to be shared widely.  
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Table 1. Assessment criteria accounted for during the HST and PACE processes 
 
Criterion to assess ultra-OMPs NICE HST 
Value 
Framework 
SMC 
ultra-OMP 
framework 
SMC PACE 
group 
(non-
exhaustive) 
Nature of the condition √ √   
Patient clinical disability with current standard care √     
Impact of the disease on family/carers' quality of life √     
Extent and nature of current treatment options √     
unmet need     √ 
severity of the condition     √ 
Impact of the new technology √ √ √ 
Clinical effectiveness √     
Overall magnitude of health benefits to patients, and 
where relevant, their families/carers 
√   √ 
Heterogeneity of health benefits within the 
population 
√     
Robustness of the current evidence base and 
anticipated contribution the guidance may make to 
strengthen in 
√     
Treatment continuation rules (if applicable) √     
Cost to the NHS and Personal Social 
Services (PSS) 
√ √   
Budget impact of technology in the NHS and PSS  √     
Robustness of costing and budget impact 
information 
√     
Patient access schemes √     
Value for money √ √   
Incremental benefit of the new technology 
compared with current treatment options (technical 
efficiency) 
√     
Nature and extent of other resources needed to √     
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enable the technology to be used (productive 
efficiency) 
Impact of the new technology on the budget 
available for specialised commissioning (allocative 
efficiency) 
√     
Opportunity cost of the technology (effect of 
investing in this technology rather than in another 
specialised service) 
√     
Impact of the technology beyond direct 
health benefits 
√ √   
Significant benefits other than health √     
Whether a substantial proportion of the costs 
(savings) or benefits are incurred outside of the NHS 
and PSS 
√     
Potential for long-term benefits to the NHS and 
society of research and innovation 
√     
Impact of the technology on the delivery of 
the specialised service 
√ √   
Staffing and infrastructure requirements √     
Training requirements and need to plan for expertise √     
Best clinical practice in delivering the service √     
Service/infrastructure changes/benefits as a result of 
using the medicine 
    √ 
Impact of the new technology on quality of 
life  
    √ 
The ability to continue to work or education     √ 
The management of symptoms such as pain and 
extreme tiredness 
    √ 
Helping relieve psychological distress     √ 
Convenience of how and where the treatment is 
received 
    √ 
The ability to self-care or maintain independence 
and dignity 
    √ 
Time for accompanied visits for treatment     √ 
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Requirement for assisting the patient with personal 
care and support 
    √ 
Out of pocket expenses     √ 
Impact on family life     √ 
Impact on the carer's ability to go to work     √ 
Clinical issues       
Specific patient groups that may benefit more from 
use of the medicine 
    √ 
Place in the patient pathway     √ 
      √ 
 
Legend: NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines 
Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; 
HST: Highly Specialised Technology; PACE: Patient and Clinical Engagement; OMP: Orphan 
Medicial Product. 
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Table 2. Products assessed by SMC ultra-orphan process and informed by PACE (May 2014 
– September 2016) 
 
Medicine Indication 
Recommendatio
n 
Economic 
evaluation* 
SMC 
modifiers 
for ultra-
orphan 
drugs 
Indications other than cancer 
Ataluren 
Duchenne muscular 
dystrophy 
Not 
recommended 
£793,498/QAL
Y versus BSC 
(Public ICER, 
ICER including 
PAS 
confidential). 
- absence of 
other 
treatments 
of proven 
benefit. 
Eculizumab 
Paroxysmal nocturnal 
haemoglobinuria 
Not 
recommended 
Cost-
consequence 
analysis: 
estimated 
incremental 
QALY gain of 
11.96 with 
eculizumab 
compared to 
BSC and a life 
year gain of 
9.23 (lifetime 
incremental 
costs 
remained in 
confidence). 
- substantial 
improveme
nt in quality 
of life, 
- absence of 
other 
treatments 
of proven 
benefit. 
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Eculizumab 
Atypical haemolytic 
uraemic syndrome 
Not 
recommended 
Cost-
consequence 
analysis: 
Estimated 
lifetime QALY 
gain of 15.3 
with 
eculizumab 
compared to 
BSC and a life 
year gain of 14 
(lifetime 
incremental 
costs 
remained in 
confidence). 
- substantial 
improveme
nt in quality 
of life, 
- potential 
to bridge to 
a definitive 
therapy, 
- absence of 
other 
treatments 
of proven 
benefit. 
Elosufase alfa 
Mucopolysaccharidosis 
type IVa 
Not 
recommended 
£829,870/QAL
Y versus 
standard 
medical care, 
including a 
PAS (simple 
discount) and 
a 3.5% 
discount rate 
applied to 
costs and 
benefits. 
£822,265/QAL
Y using a 
societal 
- absence of 
other 
treatments 
of proven 
benefit. 
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perspective. 
Ivacaftor 
Cystic fibrosis with 
certain genetic 
mutations 
Not 
recommended 
Early ivacaftor 
versus: 
- late 
ivacaftor: 
£484,386/QAL
Y 
- standard of 
care: 
£609,316/QAL
Y 
(Public ICER, 
ICER including 
PAS 
confidential). 
- absence of 
other 
treatments 
of proven 
benefit. 
Pasireotide 
Acromegaly where 
surgery is not an option 
and are inadequately 
controlled on other 
treatments 
Accepted 
£5,855/QALY 
versus 
monthly 
somatostatin 
analogues. 
- potential 
to bridge to 
a definitive 
therapy. 
Cancer indications 
Bevacizumab 
(in 
combination) 
Persistent, recurrent or 
metastatic cervical 
cancer 
Accepted 
£43,624/QALY 
for 
bevacizumab 
+ cisplatin + 
paclitaxel 
versus 
carboplatin + 
paclitaxel, 
- substantial 
improveme
nt in life 
expectancy. 
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including a 
PAS 
(confidential 
discount as a 
rebate on the 
list price of 
bevacizumab). 
Bevacizumab 
(in 
combination) 
Platinum resistant, 
recurrent epithelial 
ovarian, fallopian tube or 
primary peritoneal 
cancer 
Restricted 
£50,538/QALY 
versus 
chemotherapy 
alone.  
- absence of 
other 
treatments 
of proven 
benefit. 
Blinatumoma
b 
Philadelphia 
chromosome negative 
relapsed or refractory B-
precursor acute 
lymphoblastic leukaemia 
Accepted 
£52,201/QALY 
versus 
standard care 
(multi-drug 
chemotherapy
), including a 
PAS. 
- absence of 
other 
treatments 
of proven 
benefit,  
- potential 
to bridge to 
a definitive 
therapy. 
Bosutinib 
Previously treatment 
Philadelphia 
chromosome positive 
chronic myelogenous 
leukaemia 
Accepted 
£39,119-
£62,619/QALY 
depending on 
the model and 
disease phase 
(Public ICER, 
ICER including 
PAS (simple 
discount) 
confidential). 
- substantial 
improveme
nt in quality 
of life, 
- absence of 
other 
treatments 
of proven 
benefit. 
(resubmissio
n) 
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Brentuximab 
vedotin 
Relapsed or refractory 
CD30+ Hodgkin 
lymphoma 
Restricted 
£43,731/QALY 
in both 
subgroups 
considered.  
- substantial 
improveme
nt in life 
expectancy, 
- substantial 
improveme
nt in quality 
of life, 
-  the 
potential to 
bridge to a 
definitive 
therapy, 
- absence of 
other 
treatments 
of proven 
benefit. 
Cabozantinib 
Progressive, 
unresectable locally 
advanced or metatstatic 
medullary thyroid cancer 
Not 
recommended 
£93,141/QALY 
versus BSC. 
- absence of 
other 
treatments 
of proven 
benefit. 
Ceritinib 
Previously treated 
anaplastic lymphoma 
kinase positive advance 
non-small lung cancer 
Accepted 
£50,908/QALY 
versus BSC, 
including a 
PAS (simple 
discount).  
- substantial 
improveme
nt in life 
expectancy. 
Crizotinib 
First-line treatment of 
adults with anaplastic 
lymphoma kinase (ALK)-
Accepted 
£48,355/QALY  
versus 
pemetrexed 
- substantial 
improveme
nt in quality 
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positive advanced non-
small cell lung cancer 
plus cisplatin 
or carboplatin, 
including a 
PAS (simple 
discount). 
of life. 
Ibrutinib 
Relapsed or refractory 
mantle cell lymphoma 
Accepted 
£41,798/QALY 
versus 
physician's 
choice of 
treatment, 
including a 
PAS (discount) 
  
Idelalisib 
Refractory follicular 
lymphoma 
Accepted 
£62,653/QALY 
versus 
standard care 
(Public ICER, 
ICER including 
PAS 
confidential). 
  
Lenvatinib 
Adult patients with 
progressive, locally 
advanced or metastatic, 
differentiated 
(papillary/follicular/Hürt
hle cell) thyroid 
carcinoma , refractory to 
radioactive iodine 
Accepted 
£49,525/QALY 
versus 
sorafenib, 
including a 
PAS (simple 
discount). 
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Olaparib 
Maintenance treatment 
of platinum sensitive 
relapsed BCRA mutated 
high grade serous 
epithelial ovarian, 
fallopian tube or primary 
peritoneal cancer 
Not 
recommended 
£49,236/QALY 
versus watch 
and wait, 
including a 
PAS.  
- absence of 
other 
treatments 
of proven 
benefit. 
Regorafenib 
Unresectable or 
metastatic 
gastrointestinal stroma 
tumours 
Accepted 
£31,200/QALY 
versus BSC, 
including a 
PAS 
(confidential 
discount).  
- substantial 
improveme
nt in quality 
of life, 
- absence of 
other 
treatments 
of proven 
benefit. 
Trametinib 
In combination with 
dabrafenib for the 
treatment of adult 
patients with 
unresectable or 
metastatic melanoma 
with a BRAF V600 
mutation 
Restricted 
£35,134/QALY 
versus 
dabrafenib, 
including a 
PAS 
(discount); 
and £39, 
956/QALY 
versus 
vemurafenib, 
including a 
PAS (discount) 
- substantial 
improveme
nt in life 
expectancy,  
- substantial 
improveme
nt in quality 
of life. 
Trastuzumab 
(in 
combination) 
HER2 positive metastatic 
adenocarcinoma of the 
stomach or gastro-
Restricted 
£41,347/QALY 
versus 
epirubicin, 
- substantial 
improveme
nt in life 
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(2nd 
resubmission
) 
oesophageal junction oxaliplatin and 
capecitabine.  
expectancy, 
- absence of 
other 
treatments 
of proven 
benefit. 
 
* ICER as used for decision-making unless confidential PAS applied. Sensitivity analyses were 
performed, and various ICERs presented, but this is the ICER that appears to have been 
accounted for in the decision. 
 
Legend: SMC: Scottish Medicines Consortium; QALY: Quality-adjusted Life Years; PAS: 
Patient Access Scheme; ICER: Incremental Cost-effectiveness Ratio; BSC: Best Supportive 
Care 
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Figure 1. Conceptual framework of OMP development and assessment challenges 
 
Figure 1 illustrates the conceptual framework built summarising the challenges commonly 
encountered for OMPs, how they relate to the nature of OMPs throughout the drug 
development pathway and their implications for HTA. 
 
Legend: PRO: Patient-reported Outcomes; HRQol: Health-related Quality of life. 
 
